Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 17 of the 33 sources its claims cite were checked for support.

The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis

Open access
Tie, Shanshan, Pan, Yujia, Pang, Chenguang, Saman, Azeem, Dong, Yao, Fang, Shuguang, Zhu, Jianguo, Wu, Ying, Gu, Shaobin · 2025 · Nutrients

Abstract

Background: An imbalance in the immune system, stress response, and gut microbiota can contribute to the onset and progression of anxiety and depression. This pilot study aimed to explore the effect of Weizmannia coagulans BC99 on anxiety and depression through the gut microbiota–brain axis. Methods: A total of 79 participants with Hamilton Depression Rating Scale (HAMD-17) ≥ 8 or Hamilton Anxiety Rating Scale (HAMA-14) ≥ 7 were included and completed the study. The participants were randomly assigned to either the placebo group or the BC99 intervention group. The intervention lasted 8 weeks, with participants receiving either dextrin (3 g/day) or BC99 probiotics (3 g/day, 5 × 109 CFU) daily. Pre- and post-intervention comparisons were made on HAMD and HAMA scores, inflammatory cytokines, neurotransmitters, gut microbiota, and short-chain fatty acids. Results: Results showed that after 8 weeks, BC99 and placebo intervention were effective in reducing HAMD and HAMA scores, and HAMD and HAMA scores in BC99 group were reduced by 2.40 and 5.53 points compared the placebo group, and the response and remission rates were also higher than that of the placebo, but there was no significant difference. BC99 also could regulate the levels of inflammatory cytokines IL-17 and IL-10, and increase neurotransmitter levels of γ-GABA and NO. Moreover, compared with the placebo group, BC99 also enhanced the abundance of beneficial bacteria such as Faecalibactrium, Megamonas, Dialister, and Agathobacter, which were closely associated with clinical indicators of mental disorders, and increased the production of short-chain fatty acids. Conclusions: These preliminary findings suggested that BC99 might alleviate anxiety and depression symptoms by regulating the level of neurotransmitters or the change of microbiota, which needed further verification in subsequent animal or clinical experiments.

Overview

CoChat Summary

## TL;DR

This 8-week randomized, double-blind, placebo-controlled pilot trial tested Weizmannia coagulans BC99 in 79 adults with HAMD-17 ≥ 8 or HAMA-14 ≥ 7. BC99 showed improvements in anxiety/depression-related scores and several gut–brain axis biomarkers, but between-group differences in the main clinical outcomes were not statistically significant.

## Key findings

  • 79 participants completed the study (82 randomized; 41 placebo, 41 BC99; 79 completed).
  • HAMD-17 and HAMA-14 improved in both groups, and the BC99 group had larger reductions: HAMD decreased from 20.80 to 11.10 in BC99 vs 19.77 to 12.47 in placebo; HAMA also decreased more in BC99, but between-group differences were not significant.
  • In the BC99 group, γ-GABA increased by 0.05 μmol/L vs placebo (p < 0.001), NO decreased (p < 0.001), and Cys-C decreased from 688.90 ng/mL to 533.52 ng/mL (p < 0.001).
  • BC99 increased some gut microbiota and SCFA measures: propionic acid and isobutyric acid increased significantly (p < 0.05), and taxa including Faecalibacterium (+0.64-fold), Dialister (+4.78-fold), and Agathobacter (+1.30-fold) increased, while Escherichia-Shigella decreased (0.75-fold).

## Methods

  • Design: Randomized, double-blind, placebo-controlled pilot study with 8 weeks of intervention; registered at ClinicalTrials.gov NCT06629441 and approved by an ethics committee.
  • Sample/intervention: 82 eligible adults recruited in Luoyang, Henan, China; 79 completed. Participants were assigned 1:1 to BC99 (3 g/day; 5 × 10^9 CFU) or placebo (3 g/day dextrin).
  • Main analysis: Baseline-to-week-8 changes in HAMD-17, HAMA-14, PSQI, GSES, cytokines (IL-17, IL-10), neurotransmitters (γ-GABA, NO, Cys-C, NPY), SCFAs, and 16S rDNA gut microbiota were analyzed mainly with baseline-adjusted ANCOVA; response/remission used logistic regression; microbiota used α/β diversity and compositional analyses.

## Limitations

  • The paper states that the sample size was relatively small, which may have limited statistical power.
  • The participants were relatively young and mainly from the same country, limiting generalizability.
  • The authors state that the mechanism was not further analyzed in animal models.
  • Evident from the text: although many biomarker and microbiota changes were reported, the primary between-group HAMD/HAMA differences were not statistically significant, so the clinical efficacy remains preliminary.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu17193087

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The flow chart of the clinical trial study.
Figure 1 The flow chart of the clinical trial study.CC BY · PubMed Central
Figure 2 Comparison of general data between the two groups of participants; (A) age and (B) gender; ns: not signficant.
Figure 2 Comparison of general data between the two groups of participants; (A) age and (B) gender; ns: not signficant.CC BY · PubMed Central
Figure 3 Comparison of questionnaires before and after intervention; (A) PSQI and (B) GSES; * p < 0.05, ** p < 0.01. Note: PSQI: Pittsburgh Sleep Quality Index; GSES: General Self-efficacy Scale; ns: not significant.
Figure 3 Comparison of questionnaires before and after intervention; (A) PSQI and (B) GSES; * p < 0.05, ** p < 0.01. Note: PSQI: Pittsburgh Sleep Quality Index; GSES: General Self-efficacy Scale; ns: not significant.CC BY · PubMed Central
Figure 4 The levels of inflammatory cytokines (A) IL-17 and (B) IL-10; ** p < 0.01, *** p < 0.001. Note: IL-17: interleukin-17; IL-10: interleukin-10.
Figure 4 The levels of inflammatory cytokines (A) IL-17 and (B) IL-10; ** p < 0.01, *** p < 0.001. Note: IL-17: interleukin-17; IL-10: interleukin-10.CC BY · PubMed Central
Figure 5 Changes in neurotransmitter levels before and after BC99 and placebo intervention. (A) γ-GABA, (B) NO, (C) Cys-C, and (D) NPY. *** p < 0.001. Note: γ-GABA: γ-aminobutyric acid; NO: nitric oxide; Cys-C: cystatin C; NPY: neuropeptide Y.
Figure 5 Changes in neurotransmitter levels before and after BC99 and placebo intervention. (A) γ-GABA, (B) NO, (C) Cys-C, and (D) NPY. *** p < 0.001. Note: γ-GABA: γ-aminobutyric acid; NO: nitric oxide; Cys-C: cystatin C; NPY: neuropeptide Y.CC BY · PubMed Central
Figure 6 Effect of BC99 probiotic on gut microbiota in anxiety and depression participants. (A) Chao1 index, (B) Shannon index, (C) Veen diagram, (D) PCoA analysis, (E) Species types at phylum level, (F) Relative abundance content, and (G) The ratio of Firmicutes to Bacteroidota at phylum level; ns: not significant.
Figure 6 Effect of BC99 probiotic on gut microbiota in anxiety and depression participants. (A) Chao1 index, (B) Shannon index, (C) Veen diagram, (D) PCoA analysis, (E) Species types at phylum level, (F) Relative abundance content, and (G) The ratio of Firmicutes to Bacteroidota at phylum level; ns: not significant.CC BY · PubMed Central
Figure 7 (A) Taxonomic cladogram of the main constituent taxa of gut microbiota. (B) Distribution histogram showing the significant abundance of strains, LDA score > 2.5. (C) The relative abundance of Fusobacteriota, Firmicutes, Sutterellaceae, Barnesiellaceae, Prevotella, Lachnospira, Prevotella_unclassified, and Lachnospira_ unclassified. * p < 0.05, ** p < 0.01, and **** p < 0.0001; ns: not significant.
Figure 7 (A) Taxonomic cladogram of the main constituent taxa of gut microbiota. (B) Distribution histogram showing the significant abundance of strains, LDA score > 2.5. (C) The relative abundance of Fusobacteriota, Firmicutes, Sutterellaceae, Barnesiellaceae, Prevotella, Lachnospira, Prevotella_unclassified, and Lachnospira_ unclassified. * p < 0.05, ** p < 0.01, and **** p < 0.0001; ns: not significant.CC BY · PubMed Central
Figure 8 The content of SCFAs in feces. The concentration of (A) total SCFAs, (B) acetic acid, (C) propionic acid, (D) butyric acid, and (E) isobutyric acid. * p < 0.05.
Figure 8 The content of SCFAs in feces. The concentration of (A) total SCFAs, (B) acetic acid, (C) propionic acid, (D) butyric acid, and (E) isobutyric acid. * p < 0.05.CC BY · PubMed Central
Figure 9 Spearman’s correlation heatmap analysis of the influence of gut microbiota. * p < 0.05, ** p < 0.01.
Figure 9 Spearman’s correlation heatmap analysis of the influence of gut microbiota. * p < 0.05, ** p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 12 Not checked · 102 Own results and interpretations

40 more claims

Create a free account to see all 128 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 65
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 58 references

Cited by

See all 11

Metadata

Authors
Tie, S., Pan, Y., Pang, C., Saman, A., Dong, Y., Fang, S., Zhu, J., Wu, Y., & Gu, S.
Affiliations
  • Henan University of Science and Technology (CN)
  • College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471000, China
  • Wecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou 215200, China
Corresponding author
  • Wu, Ying
  • Gu, Shaobin
Venue
Nutrients
Publisher
MDPI AG
Published
2025-09-28
Volume
17
Issue
19
Pages
3087
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4414623064
Cited by
11
References
58
Citations by year
2026: 11
FWCI
5.15
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Major Science and Technology Special Projects in Henan Province (231100310200)
  • Key R&D Projects in Henan Province (241111314200, 221111111400)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
probiotics, anxiety, depression, gut-brain axis, inflammatory cytokines, IL-17, IL-10, GABA, nitric oxide, short-chain fatty acids, Megamonas, Dialister, Agathobacter, neurotransmitters
MeSH terms
Eubacteriales, Gastrointestinal Microbiome, Adult, Anxiety, Brain, Depression, Fatty Acids, Volatile, Female, Humans, Male, Middle Aged, Pilot Projects, Cytokines, Treatment Outcome, Probiotics, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis. https://app.cochat.ai/papers/10.3390/nu17193087
The paper
Tie, S., Pan, Y., Pang, C., Saman, A., Dong, Y., Fang, S., Zhu, J., Wu, Y., & Gu, S. (2025). The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis. Nutrients. https://doi.org/10.3390/nu17193087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.